Palmer Ashleigh 4
4 · Provention Bio, Inc. · Filed Feb 14, 2023
Insider Transaction Report
Form 4
Palmer Ashleigh
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2023-02-10$2.50/sh+50,000$125,000→ 2,620,050 total - Sale
Common Stock
2023-02-10$10.11/sh−50,000$505,555→ 2,570,050 total - Exercise/Conversion
Common Stock
2023-02-13$2.50/sh+25,835$64,588→ 2,595,885 total - Sale
Common Stock
2023-02-13$10.04/sh−25,835$259,448→ 2,570,050 total - Exercise/Conversion
Stock Option (right to buy)
2023-02-10−50,000→ 467,555 totalExercise: $2.50Exp: 2027-04-25→ Common Stock (50,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2023-02-13−25,835→ 441,720 totalExercise: $2.50Exp: 2027-04-25→ Common Stock (25,835 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.28 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.42 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option is fully vested.